Skip to main content

Universe Pharmaceuticals INC

corporate_fare Company Profile

Universe Pharmaceuticals INC

UPC·NASDAQ·Life Sciences·CIK 0001809616

Universe Pharmaceuticals INC manufactures, markets, distributes, and sells traditional Chinese medicine derivative products in China. The company's products address common chronic health conditions in the elderly, focusing on physical wellness and longevity, and also include cold and flu medications. Key products include guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. Additionally, Universe Pharmaceuticals INC distributes and sells third-party products such as biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. The company serves pharmaceutical companies, hospitals, clinics, and drugstore chains. Founded in 1998, Universe Pharmaceuticals INC is headquartered in Ji'An, China, and operates as a subsidiary of Sununion Holding Group Limited.

Universe Pharmaceuticals INC (NASDAQ:UPC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for UPC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-01, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for UPC spans 6-K, SCHEDULE 13D, 20-F.

Recent high-impact activity:

  • Universe Pharmaceuticals Seeks Shareholder Approval for 1-for-10 Reverse Split to Regain Nasdaq Compliance
  • Universe Pharmaceuticals closes $10.75M Best Praise acquisition, issuing 4.38M shares
  • Universe Pharma Posts $9M Revenue, $1.6M Loss; Unveils $10.75M All-Stock Deal
  • Universe Pharmaceuticals to Acquire Best Praise for $10.75M in Stock, Causing Over 1000% Dilution
  • Universe Pharmaceuticals to Acquire 100% of Best Praise International

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$17.86B
Net Income
-$3.67B
Diluted EPS
-$8.06
Op. Cash Flow
-$5.05B
Free Cash Flow
-$5.32B
Gross Profit
$6.3B
Operating Income
-$2.92B
Cash & Equivalents
$33.59B
Total Debt
$2.11B
Debt / Equity
0.04×
Net Margin
-20.6%
Shares Outstanding
563.34K sh
Source: 20-F · filed 2026-01-29 · accession 0001213900-26-009000

Dilution Risk

Low risk

Filing-implied dilution signals for UPC, detected from its recent SEC filings · based on capital-structure filings through 2026-05-14.

Significant Share Grant to CEO · Material Dilution

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

UPC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with U →
$4.36
52-week range · as of 2026-09-01 $2 – $17.96
Market cap
$21.91M
Volume
145.2K (0.1× avg)
3-mo avg 1.6M
Live data · 2026-09-14 03:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed UPC - Latest Insights

UPC
Sep 01, 2026, 5:25 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.27
Real-time Price: $4.36 info
Change: +$0.090 (+2%) info
Market Cap: $21.906M info
UPC
Jul 31, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.88
Real-time Price: $4.36 info
Change: +$0.480 (+12%) info
Market Cap: $21.906M info
UPC
Jul 29, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $4.36 info
Change: +$1.11 (+34%) info
Market Cap: $21.906M info
UPC
Jun 26, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.46
Real-time Price: $4.36 info
Change: -$0.100 (-2%) info
Market Cap: $21.906M info
UPC
Jun 26, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.03
Real-time Price: $4.36 info
Change: +$1.33 (+44%) info
Market Cap: $21.906M info
UPC
May 21, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $2.69
Real-time Price: $4.36 info
Change: +$1.67 (+62%) info
Market Cap: $21.906M info
UPC
May 14, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $4.36 info
Change: +$1.68 (+63%) info
Market Cap: $21.906M info
UPC
Apr 16, 2026, 4:10 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.25
Real-time Price: $4.36 info
Change: +$1.11 (+34%) info
Market Cap: $21.906M info
UPC
Feb 11, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.62
Real-time Price: $4.36 info
Change: +$0.740 (+20%) info
Market Cap: $21.906M info
UPC
Jan 28, 2026, 7:34 PM EST
Filing Type: 20-F
Importance Score:
9
Price at Filing: $4.22
Real-time Price: $4.36 info
Change: +$0.140 (+3%) info
Market Cap: $21.906M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets